References
- Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007;13:116–123.
- Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007;21: 2540–2544.
- Kuroswa S, Fukuda T, Tajima K, et al. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation. Am J Hematol 2009;84:815–820.
- Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012;119:1599–1606.
- Savani BN, Mielke S, Reddy N, et al. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009;44:769–777.
- Porter DL, Alyea EP, Antin JH, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16: 1467–1503.
- Van den Brink MRM, Porter DL, Giralt S, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010;16:S138–S145.
- Kroger N. Approaches to relapse after allogeneic stem cell transplantation. Curr Opin Oncol 2011;23:203–208.
- Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 2013;48:452–458.
- Kolb HJ, Schattenberg A, Goldman JM, et al. Graft- versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041–2050.
- Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004;89:998–1008.
- Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007;25:4938–4945.
- Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor Leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433–444.
- Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion:a high incidence of extramedullary relapse. Leukemia 2004; 18:1789–1797.
- Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:483–493.
- Cardoso A, Schultze J, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T cell anergy to alloantigen. Blood 1996;88:41–48.
- Galandrini R, Albi N, Zarcone D, et al. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptortriggered cytotoxicity. Eur J Immunol 1992;22:2047–2053.
- Han P, Story C, McDonald T, et al. Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. Cytotherapy 2002;4:165–175.
- Shaw BE, Russel NH. Treatment options for the management of acute leukemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008;41:495–503.
- Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012;26:1211–1217.